cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
47 own
67 watching
Current Price
$2.47
$-0.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
36.86M
52-Week High
52-Week High
13.49000
52-Week Low
52-Week Low
2.25900
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
14.8675
iconMarket Capitalization36.86M
icon52-Week High13.49000
icon52-Week Low2.25900
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio14.8675
What does the Stockal+Disclaimer.pdf do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
9 months ago
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of...
Zolmax
11 months ago
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV Get Rating) in a research note released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical companys stock. Separately, HC Wainwright reaffirmed a neutral rating and set a $8.00 price objective...
Globe Newswire
1 year ago
Company to Host Conference Call Today at 8:30 a.m. ETBURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business ...
Globe Newswire
1 year ago
Management to Host Conference CallBURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release ...
Globe Newswire
1 year ago
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on November 30...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$2.47
$-0.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00